REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells.
Identification of reliable markers of chemo- and radiosensitivity and the key molecules that enhance the susceptibility of squamous esophageal cancer cells to anticancer treatments would be highly desirable. To test whether regenerating gene (REG) I expression enhances chemo- and radiosensitivity in esophageal squamous cell carcinoma cells, we used MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays to compare the chemo- and radiosensitivities of untransfected TE-5 and TE-9 cells with those of cells stably transfected with REG Ialpha and Ibeta. We then used flow cytometry to determine whether REG I expression alters cell cycle progression. No REG I mRNA or protein were detected in untransfected TE-5 and TE-9 cells. Transfection with REG Ialpha and Ibeta led to strong expression of both REG I mRNA and protein in TE-5 and TE-9 cells, which in turn led to significant increases in both chemo- and radiosensitivity. Cell cycle progression was unaffected by REG I expression. REG I thus appears to enhance the chemo- and radiosensitivity of squamous esophageal cancer cells, which suggests that it may be a useful target for improved and more individualized treatments for patients with esophageal squamous cell carcinoma.
Hayashi
Kaori
K
Department of Biochemistry, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Motoyama
Satoru
S
Koyota
Souichi
S
Koizumi
Yukio
Y
Wang
Jingshu
J
Takasawa
Shin
S
Itaya-Hironaka
Asako
A
Sakuramoto-Tsuchida
Sumiyo
S
Maruyama
Kiyotomi
K
Saito
Hajime
H
Minamiya
Yoshihiro
Y
Ogawa
Jun-Ichi
J
Sugiyama
Toshihiro
T
D000964:Antimetabolites, Antineoplastic / Q000378:metabolism / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D005472:Fluorouracil / Q000378:metabolism* / Q000627:therapeutic use; D005562:Formazans / Q000378:metabolism; D006801:Humans; D051847:Lithostathine / Q000235:genetics / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011836:Radiation Tolerance / Q000235:genetics*; D013778:Tetrazolium Salts / Q000378:metabolism; D014162:Transfection
D000964:Antimetabolites, Antineoplastic; D005562:Formazans; D051847:Lithostathine; D011506:Proteins; C497617:REG1A protein, human; D012333:RNA, Messenger; D013778:Tetrazolium Salts; C079782:MTT formazan; D005472:Fluorouracil